(Q35961095)

11 August 2017

1 reference

title

Pimecrolimus -- an anti-inflammatory drug targeting the skin (English)

1 reference

11 August 2017

0 references

Grassberger M

1

1 reference

11 August 2017

Steinhoff M

series ordinal

2

1 reference

11 August 2017

Schneider D

series ordinal

3

1 reference

11 August 2017

Luger TA

series ordinal

4

1 reference

11 August 2017

publication date

1 December 2004

1 reference

11 August 2017

published in

Experimental Dermatology

1 reference

11 August 2017

volume

13

1 reference

11 August 2017

issue

12

1 reference

11 August 2017

page(s)

721-730

1 reference

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

Pimecrolimus does not affect Langerhans cells in murine epidermis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0906-6705.2004.00269.X

10.1111/J.0906-6705.2004.00269.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference